Cannabis
Cannabis is administered three times daily during the active cannabis treatment period.
Loading study record…
Loading study record…
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-08-20
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Cannabis is administered three times daily during the active cannabis treatment period.
Matched placebo cannabis is administered three times daily during the placebo treatment period.
Intranasal opioid agonists are administered during sample and self-administration sessions
Oral opioid agonist maintenance doses are administered four times daily throughout study participation.
Eligibility
primary outcomes
Time frame: Up to 6.5 Weeks
Number of drug-choice trials completed for intranasal opioid agonists during self-administration sessions.
Publications
No exact PMID-linked public article is currently readable locally.